SAN FRANCISCO, Feb. 6 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals , a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Lawrence K. Cohen Ph.D., chief executive officer of VIA, will present a company update at the 2008 BIO CEO & Investment Conference on Tuesday, February 12, 2008, at 1:15 p.m. ET at the Waldorf-Astoria hotel in New York.
Interested parties may access a live audio webcast of the presentation from the investor section of the VIA website, http://www.viapharmaceuticals.com. A replay of the presentation will be archived on the site for at least one week following the presentation.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company’s lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.
CONTACT: James G. Stewart, Senior Vice President and Chief Financial
Officer of VIA Pharmaceuticals, Inc., +1-415-283-2204; or Media, Aimee
Corso of WeissComm Partners, +1-310-780-2661, acorso@wcpglobal.com, for VIA
Pharmaceuticals, Inc.; or Investors, San Francisco, Ian Clements, or Lauren
Glaser, both +1-415-392-3385, or New York City, Brian Korb,
+1-646-378-2923, all of The Trout Group, for VIA Pharmaceuticals, Inc.
Web site: http://www.viapharmaceuticals.com/
